Literature DB >> 28258590

Health-related quality of life among children with hereditary angioedema.

Batya Engel-Yeger1, Henriette Farkas2, Shmuel Kivity3, Nóra Veszeli2, Kinga Viktória Kőhalmi2, Aharon Kessel4.   

Abstract

BACKGROUND: The clinical expressions of hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE) and its related burden may negatively affect patient quality of life. This study aimed to assess health-related quality of life (HRQoL) in children with C1-INH-HAE.
METHODS: Children (N = 98: 34 C1-INH-HAE patients, 64 healthy controls) aged 3-18 years were recruited in Israel and Hungary. All individuals completed a demographic questionnaire, a disease activity and site questionnaire, and the Pediatric Quality of Life Inventory (PedsQL™) 4.0 Generic Core Scales (child self-report and maternal proxy report) to assess HRQoL.
RESULTS: Among C1-INH-HAE patients, nine (26.5%) had 1-5 attacks/year, six (17.6%) had 6-18 attacks/year, eight (23.5%) had 25-60 attacks/year, and 11 (32.4%) were asymptomatic over the previous year. Children with C1-INH-HAE attacks demonstrated lower HRQoL than healthy control children across the total score, school, and psychosocial dimensions of the PedsQL™. The number of C1-INH-HAE attacks negatively correlated with the total HRQoL score (r = -0.48, p = 0.008), school-related HRQoL (r = -0.39, p = 0.02), and psychosocial HRQoL (r = -0.43, p = 0.01). Patients with multisite laryngeal, abdominal, and peripheral C1-INH-HAE attacks had a lower HRQoL compared with those who experienced solely peripheral attacks across the total score (p = 0.04), physical (p = 0.04), and school (p = 0.02) domains. There was no significant difference between asymptomatic C1-INH-HAE patients and healthy controls.
CONCLUSIONS: Children with symptomatic C1-INH-HAE demonstrate impaired HRQoL compared with healthy controls. HRQoL was affected by the frequency and site of C1-INH-HAE attacks and mostly in the school and physical domains.
© 2017 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.

Entities:  

Keywords:  C1-inhibitor; PedsQL™ 4.0; children; complement-1 esterase inhibitor defects; hereditary angioedema; quality of life; symptom assessment

Mesh:

Substances:

Year:  2017        PMID: 28258590     DOI: 10.1111/pai.12712

Source DB:  PubMed          Journal:  Pediatr Allergy Immunol        ISSN: 0905-6157            Impact factor:   6.377


  9 in total

1.  Hereditary angioedema from the patient's perspective: A follow-up patient survey.

Authors:  Aleena Banerji; Yu Li; Paula Busse; Marc A Riedl; Nicole S Holtzman; Huamin Henry Li; Mark Davis-Lorton; Jonathan A Bernstein; Michael Frank; Anthony J Castaldo; Janet Long; Bruce Zuraw; William Lumry; Sandra Christiansen
Journal:  Allergy Asthma Proc       Date:  2018-05-01       Impact factor: 2.587

Review 2.  Pharmacological Management of Hereditary Angioedema with C1-Inhibitor Deficiency in Pediatric Patients.

Authors:  Henriette Farkas
Journal:  Paediatr Drugs       Date:  2018-04       Impact factor: 3.022

Review 3.  Patient-reported Outcome Measures for Angioedema: A Literature Review.

Authors:  Anna Trier Heiberg Brix; Henrik Balle Boysen; Karsten Weller; Teresa Caballero; Anette Bygum
Journal:  Acta Derm Venereol       Date:  2021-05-19       Impact factor: 3.875

Review 4.  Disease Severity, Activity, Impact, and Control and How to Assess Them in Patients with Hereditary Angioedema.

Authors:  Anette Bygum; Paula Busse; Teresa Caballero; Marcus Maurer
Journal:  Front Med (Lausanne)       Date:  2017-12-04

5.  A randomized trial of human C1 inhibitor prophylaxis in children with hereditary angioedema.

Authors:  Emel Aygören-Pürsün; Daniel F Soteres; Sandra A Nieto-Martinez; Jim Christensen; Kraig W Jacobson; Dumitru Moldovan; Arthur Van Leerberghe; Yongqiang Tang; Peng Lu; Moshe Vardi; Jennifer Schranz; Inmaculada Martinez-Saguer
Journal:  Pediatr Allergy Immunol       Date:  2019-05-29       Impact factor: 6.377

6.  Recombinant human C1 esterase inhibitor treatment for hereditary angioedema attacks in children.

Authors:  Avner Reshef; Vesna Grivcheva-Panovska; Aharon Kessel; Shmuel Kivity; Maria Klimaszewska-Rembiasz; Dumitru Moldovan; Henriette Farkas; Vaclava Gutova; Stephen Fritz; Anurag Relan; Bruno Giannetti; Markus Magerl
Journal:  Pediatr Allergy Immunol       Date:  2019-05-29       Impact factor: 6.377

7.  Hereditary angioedema: the challenges of cross-border family investigation and treatment.

Authors:  Anna Trier Heiberg Brix; Trine Mehlbye Svensson; Malin Sandberg; Anette Bygum
Journal:  BMJ Case Rep       Date:  2020-04-14

8.  Emotional processes and stress in children affected by hereditary angioedema with C1-inhibitor deficiency: a multicenter, prospective study.

Authors:  Livia Savarese; Maria Bova; Raffaella De Falco; Maria Domenica Guarino; Raffaele De Luca Picione; Angelica Petraroli; Riccardo Senter; Claudia Traverso; Matteo Zabotto; Andrea Zanichelli; Eugenio Zito; Maria Alessio; Mauro Cancian; Marco Cicardi; Adriana Franzese; Roberto Perricone; Gianni Marone; Paolo Valerio; Maria Francesca Freda
Journal:  Orphanet J Rare Dis       Date:  2018-07-13       Impact factor: 4.123

9.  Long-Term Efficacy of Subcutaneous C1 Inhibitor in Pediatric Patients with Hereditary Angioedema.

Authors:  Donald Levy; Teresa Caballero; Iftikhar Hussain; Avner Reshef; John Anderson; James Baker; Lawrence B Schwartz; Marco Cicardi; Subhransu Prusty; Henrike Feuersenger; Ingo Pragst; Michael E Manning
Journal:  Pediatr Allergy Immunol Pulmonol       Date:  2020-09-16       Impact factor: 1.349

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.